A detailed history of Daiwa Securities Group Inc. transactions in Regenxbio Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 146 shares of RGNX stock, worth $1,112. This represents 0.0% of its overall portfolio holdings.

Number of Shares
146
Previous 146 -0.0%
Holding current value
$1,112
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 05, 2021

BUY
$29.09 - $45.68 $1,803 - $2,832
62 Added 73.81%
146 $6,000
Q1 2021

May 03, 2021

BUY
$33.61 - $49.95 $470 - $699
14 Added 20.0%
84 $3,000
Q4 2020

Feb 04, 2021

SELL
$26.52 - $49.35 $3,659 - $6,810
-138 Reduced 66.35%
70 $3,000
Q4 2019

Jan 31, 2020

SELL
$34.54 - $44.87 $828 - $1,076
-24 Reduced 10.34%
208 $9,000
Q1 2019

Apr 26, 2019

BUY
$40.82 - $62.45 $2,449 - $3,747
60 Added 34.88%
232 $13,000
Q1 2018

May 02, 2018

BUY
$24.05 - $37.5 $4,136 - $6,450
172 New
172 $5,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $329M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.